

Attorney Docket No. P70055US0
Application No. 10/506,423

Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1-10 (cancelled).

11 (new): A method of influencing the activity of an inflammatory mediator comprising administering an effective amount of a ubiquinone to a patient in need thereof.

12 (new): The method of claim 11 wherein the mediator is a histamine.

13 (new): The method of claim 11 wherein the mediator is selected from the group consisting of platelet activating factor (PAF) and a leukotriene.

14 (new): The method of claim 11 for treating the patient to influence a physiological effect selected from the group consisting of bronchoconstriction of the lung, pulmonary vascular resistance, elasticity of the lung, bowel contraction, epithelial constriction, vascular contraction,

Attorney Docket No. P70055US0
Application No. 10/506,423

catecholamine release from the adrenal medulla, histamine-caused itching and pain at nerve ends, excessive secretion of gastric juice, tachycardia, and positive-ionotropic effect on the heart.

15 (new): The method of claim 11 wherein the ubiquenone is in the form of nanoparticles having a size of from 10 to 1000 nm.

16 (new): The method of claim 11 wherein the ubiquenone is a ubidacarenone.

17 (new): The method of claim 11 wherein the ubiquenone is 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone.

18 (new): The method of claim 11 wherein the ubiquenone is in a form for administration selected from the group consisting of oral, inhalatory, intravenous, intraarterial, subcutaneous, intracutaneous, intramuscular, and topical.

19 (new): The method of claim 11 wherein the activity of the inflammatory mediator is reduced.

20 (new): The method of claim 19 wherein the mediator is a histamine.

Attorney Docket No. P70055US0
Application No. 10/506,423

- 21 (new): The method of claim 19 for treating the patient for a pathological condition selected from the group consisting of bronchitis, pneumonia, allergic asthma, multiple chemical sensitivity, hay fever, hypersensitivity reaction of immediate type (type 1), endotoxin shock, pharmaceutical-induced histamine release, skin disease, renal insufficiency, and a burn.
- 22 (new): The method of claim 19 for treating the patient for a pharmaceutical-induced histamine release.
- 23 (new): The method of claim 19 for treating the patient for a pharmaceutical-induced histamine release wherein the pharmaceutical is selected from the group consisting of D-tubocurarin, suxamethonium, an opiate, an X-ray contrast agent, a narcotic, chloroquine, and a combination thereof.
- 24 (new): The method of claim 19 wherein the ubiquenone is a ubidacarenone.
- 25 (new): The method of claim 19 wherein the ubiquenone is 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone.

Attorney Docket No. P70055USO
Application No. 10/506,423

26 (new): The method of claim 19 wherein the ubiquenone is in a form for administration selected from the group consisting of oral, inhalatory, intravenous, intraarterial, subcutaneous, intracutaneous, intramuscular, and topical.